Juno Therapeutics Upgraded By Vetr Top Raters, 100% Of Crowd Bullish

Shares of Juno Therapeutics Inc JUNO have lost nearly 20 percent since the start of 2016 and around 25 percent over the past year. The stock's underperformance likely prompted Vetr top raters to recognize value in a beaten up stock. Vetr top raters upgraded Juno Therapeutics' stock rating to 4.5-stars out of a possible 5-stars. In fact, shares of Juno Therapeutics have risen to $33.91 since the prior rating of 4.0-stars was issued just 2 days ago. Related link: Here's how crowdsourced ratings can beat the market.

In addition to an upgrade to bull-territory, 100 percent of the crowd's ratings are bullish and the crowd sourced price target of $39.61 implies a potential upside of nearly 15 percent.